GlassScriptPhysician profile
Robert P Matusz
NPI 1316931843
$2,602.29
in general payments reported to CMS, 2019-2025
21 companies · $272 in 2025
The $272 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $241 · 2021: $186 · 2022: $386 · 2023: $324 · 2024: $525 · 2025: $272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $911.83 | 2021-2025 | Nuzyra |
| Smith+Nephew, INC. | $452.99 | 2019-2022 | |
| Kci USA, INC. | $152.95 | 2019-2023 | Tegaderm, Activ.A.C. Ion Progress, Promogran Prisma |
| Averitas Pharma INC. | $148.06 | 2023-2025 | Qutenza |
| Medtronic, INC. | $147.77 | 2023-2024 | Intellis Adaptivestim |
| Next Science LLC | $112.40 | 2023-2025 | Xperience, Blastx, Surgx |
| Horizon Therapeutics Plc | $94.19 | 2019 | |
| Amgen INC. | $86.05 | 2024-2025 | Krystexxa |
| Merck Sharp & Dohme LLC | $76.73 | 2019 | |
| Reprise Biomedical, INC. | $68.54 | 2024 | Miro3d |
| Alfasigma USA, INC. | $63.33 | 2020-2021 | |
| Melinta Therapeutics, LLC | $57.33 | 2019 | |
| Convatec INC. | $34.24 | 2019-2020 | |
| Grt US Holding, INC. | $33.14 | 2021 | |
| Organogenesis INC. | $32.73 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $32.14 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Stryker Corporation | $31.24 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.71 | 2023 | Jublia |
| Vertex Pharmaceuticals Incorporated | $17.66 | 2025 | |
| Nabriva Therapeutics, Plc | $14.84 | 2022 | |
| Terumo Medical Corporation | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Matusz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.